Table 1.
Baseline characteristics of enrolled patients
| Table 1 | CKD Stages I-V | Control group | p |
|---|---|---|---|
| N=80 | N=24 | ||
| Age | 67.2 ± 11.7 | 61.2 ± 9.6 | 0.042 |
| Gender (males %) | 56.2% | 29.2% | 0.01 |
| Diabetes mellitus | 33.3% | 0% | 0.0022 |
| Atrial fibrillation | 20.83% | 13.79% | NS |
| Hypertension | 88.3% | 37.5% | <0.0001 |
| Lipid disorders | 30.6% | 41.4% | 0.039 |
| Heart failure | 63.9% | 0% | <0.0001 |
| Hypertensive nephropathy | 5.6% | 0% | NS |
| Diabetic nephropathy | 4.2% | 0% | NS |
| Beta-blockers | 61% | 20,8% | <0.007 |
| CA-blockers | 40.5% | 8.3% | 0.004 |
| ACE inhibitors | 69.6% | 41% | 0.011 |
| Diuretics | 90.5% | 16.7% | <0.0001 |
| Statins | 97.5% | 43% | <0.0001 |
| Erythropoietina | 5.6%a | 0% | <0.0001 |
| Mean dialysis vintage [months]a | 27±9a | 0 | <0.0001 |
a applies only to CKD stage V patients